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ABSTRACT 
Objective: Levodropropizine is a novel antitussive drug, which occurs as enantiomers. They are levodropropizine (2S) [LDP] and 
dextrodropropizine (impurity A) (2R) [DDP]. An isocratic chiral high performance liquid chromatographic (Normal phase HPLC) method has been 
developed and validated for simultaneous determination of dropropizine enantiomers along with non-polar impurity-B, (1-phenyl piperazine) [1-
PP] in raw material and in dosage forms.  
Methods: The compounds were separated on chiral stationary phase (CSP) Chiralpak AD-H column, with a mixture of n-hexane, anhydrous ethanol, 
diethyl amine (DEA) in the ratio of 55:45:0.1 v/v as mobile phase at a flow rate of 1.4 ml/min. UV detection was performed at 254 nm. The method 
was validated for accuracy, precision, specificity, linearity, and sensitivity. The developed and validated method was successfully used for 
quantitative analysis of commercially available Tablets. 
Results: Total chromatographic analysis time per sample was ~5 min. with 1-PP, levodrpropizne, dextropropizine eluting with retention times of 
2.5 min., 3.05 min., and 3.66 min., respectively. Validation studies revealed the method is specific, rapid, reliable and reproducible for 
levodropropizne and its impurity A and non chiral impurity B. Calibration plots were linear over the concentration ranges 0.5-5 µg/ml and 0.5-5 
µg/ml for levodropropizine and dextrodropropizine respectively.  
Conclusion: The high recovery and low relative standard deviation confirm the suitability of the method for determination of dropropizine 
compounds in commercial tablets. 
Keywords: Chiral stationary phase, Chiral separation, Column liquid chromatography, Levodropropizine, Optimization mobile phase. 
 
INTRODUCTION 
Levodropropizine [S (-)-3-(4-Phenyl piperizine-1-yl) –propane -1, 2 
- diol] (LDP) (Fig.1) is used as an antitussive drug in clinical on the 
central nervous system, with a reduced sedative effect. The sedative 
effect is attributable to the chiral impurity A (Fig.2), namely dextro 
dropropizine enantiomer (DDP) [1, 2]. In the literature, many HPLC 
methods for the determination of LDP, DDP in formulation and 
biological matrices are reported. Recently, a chiral method for the 
determination of enantiomer separation using Chiral OC Column 
was reported by Huang Yong et al. [3], show RSD ratio area of LDP 
vs. DDP. The chiral separation of dropropizine enantiomers utilizing 
a Chiral OJ-H analytical column used normal phase solvents with run 
time of ~12 min was reported by K. Valliappan et al. [4]. The 
enantiomeric separation of dropropizine in biological matrices using 
LC-MS-MS was reported by Yunbiao Tang et al. [5]. A HPLC method 
for the separation of dropropizine enantiomers using normal phase 
Chiral OD column, with the run time of > 40 min was reported in BP 
2007[6]. 
 
Fig. 1: Levodropropizine (LDP) 
 
 
Fig. 2: Impurity A 
(2R)-3-(4-phenylpiperazin-1-yl) propane-1, 2-diol (dextro 
dropropizine, DPP)  
All the reported methods present limitations, viz. expensive 
instrumentation (LC-MS-MS), were having excess run time, making 
them unsuitable for routine use. The reported methods envisage 
chiral optimizations as the only goal, without considering the 
analysis of dropropizine impurities. To overcome these drawbacks, 
it is necessary to develop a simple chiral HPLC method for the 
simultaneous determination and optimization of LDP and its 
impurities A, B, which has not been reported so far. This manuscript 
describes the development and validation of a rapid, simple, robust 
enantiospecific HPLC method for simultaneous determination of 
LDP, and its impurities A, B in pharmaceutical formulations. The 
availability of an analytical method allows the estimation of active 
principal LDP, together with its chiral impurity DDP and non-polar 
achiral impurity B (1-Phenyl Piperazine) (Fig.3) present in a sample, 
alone or in combination. A commercially available pharmaceutical 
product (Levotuss) was analysed in order to check the validity of the 
proposed method. 
 
Fig. 3: Impurity B: 1-phenyl piperazine, (1-PP) 
 
MATERIALS AND METHODS 
Apparatus  
Chromatographic measurements were made on an Isocratic Shimadzu 
(Tokyo, Japan) model which consisted of one LC 20AD solvent delivery 
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module, a SPD-M 20A PDA detector, and a Rheodyne injector (model 
7725i, USA) valve fitted with a 20 µl loop. The system was controlled 
through a system controller (CBM10A) and a personal computer using a 
Shimadzu chromatographic software (LC solution. Release 1.11 SP1) 
installed on it. The mobile phase was degassed using Branson sonicator 
(Branson Ultrasonics, USA). Absorbance spectra were recorded using an 
UV-Visible spectrophotometer (Model UV-1601PC; Japan) employing 
quartz cell of 1.00 cm of path length. 
Software 
Capacity factor k1 , Selective Retention α, Resolution Rs1,2 Rs2,3,
Chemicals and reagents 
 
Tailing factor, Theoretical plates were calculated by Shimadzu LC 
solution software. The rest of the calculations were performed by 
use of Microsoft Excel 2007 software (Microsoft, USA) 
Working standards of LDP and certified reference sample mixture (CRS) 
of LDP and DPP were provided by M/S FDC, Mumbai, India. Non polar 
impurity B (1-PP) (>99%) make Aldrich used as internal standard was 
procured from M/S Chandanmal, Chennai. HPLC grade n-hexane and 
diethyl amine AR grade supplied by M/S SD Fine Chemicals (Mumbai, 
India). Ethanol absolute for analysis Ph Eur supplied by M/S Merck 
chemicals (Mumbai India). The pharmaceuticals Levotuss tablet was free 
gift from Hyundai Pharm Co. Kr.  
Standard solutions 
Stock standard solutions of LDP, Chiral Impurity A (DDP) CRS 
mixture and relative non polar impurity B (1-PP) were prepared in 
solvent mixture of anhydrous ethanol, n-hexane (40:60 v/v). The 
prepared stock solution was stored at 4 o
Sample preparation 
C protected from light. 
Working standard solutions were freshly obtained by diluting the 
standard solutions with the solvent mixture during the analysis day. 
Calibration curves reporting peak area ratios of LDP and DDP were 
established in the range of 0.5 – 25 µg/ml for all analytes in the 
presence of impurity B (1-PP).  
Twenty tablets were weighed and finely powdered. An amount of 
Pharmaceutical products equivalent to 100 mg of LDP was 
accurately weighed and transferred in a 50 ml volumetric flask. A 
suitable quantity of IS (1-PP) 5 mg was added followed by 25 ml of 
solvent mixture. The mixture was subjected to sonication for 10 min 
for complete extraction of drugs and the solution was made up to 
the mark with solvent mixture to obtain a concentration of LDP and 
1-PP as 10.0 and 0.5 µg/ml respectively. The solution was 
centrifuged at 4000 rpm for 10 min. The clear supernatant was 
collected and filtered through 0.2 µm membrane filter (Gelman 
Science, India) and 20 µl of this was injected for HPLC analysis. 
Chromatographic procedure 
Chromatographic separations were carried out on a Daicel CSP 
namely, Chiralpak AD-H (150 mm x 4.6 mm i. d., 5 µm) connected 
with a daicel security guard cartridge (4 mm x 10 mm id. 5 µm). 
Based on the PDA data, a wavelength of 254 nm was selected for 
detection. The mobile phase of hexane: anhydrous alcohol: DEA 
(55:45:0.1% v/v) was used as the mobile phase. An injection volume 
of the sample was 20 µl. The HPLC system was used in an air 
conditioned laboratory atmosphere (25± 2o
Validation 
C). 
Validation studies were conducted using the optimized assay 
conditions based on the principles of validation described in ICH 
guidelines Q2(R1) - ICH [7]. Key analytical parameters including 
specificity, accuracy, precision, linearity, detection limit, and 
quantitation limit were evaluated. Calibration curves constructed in 
a low region of 0.05- 1.0% of the target analytes concentration for 
the limit of detection and quantification. 
RESULTS AND DISCUSSION 
Optimizing parameters and analysis 
Column chemistry, solvent selectivity (solvent type), solvent 
strength (volume fraction of organic solvents in the mobile phase), 
additive strength, detection wavelength, and flow rate were varied 
to determine the chromatographic conditions giving the best 
separation. The mobile phase conditions were optimized so the peak 
from the first eluting compound did not interfere with those from 
the solvent, excipients and other components. Other criteria, viz. 
time required for analysis, appropriate k range (1< k <10) for eluted 
peaks, assay sensitivity, solvent noise, and use of the same solvent 
system for extraction of drug from formulation matrices during drug 
analysis, were also considered. After each change of mobile phase, 
the column was re-equilibrated by passage of at least ten column 
volumes of the new mobile phase. [8] 
BP 2007 monographs specified Chiralcel OD column for separation 
of LDP and DPP. Normal phase Chiralcel column contains cellulose 
backbone in the helical structure, which is loosely packed can 
readily accommodate enantiomer interaction with greater binding 
to site leading to very lengthy separation run time of around 40 min 
under the conditions for these compounds. The experiment used 
Daicel Chiralpak AD-H column having amylose core as backbone, 
which being more tightly coiled leading to early separation run time 
of around 12 min under the same conditions. Moreover Chiralpak 
AD-H having 5 µm particle sizes withstood high pressure (operate 
up to 150 kgf), leading to reasonable theoretical plates ~ 4996, 
meaning longer lifetime for the column. 
To investigate the appropriate wavelength for simultaneous 
determination of LDP, DDP, solutions of these compounds in mobile 
phase were scanned by UV–visible spectrometry (Shimadzu, Japan; 
model UV-1601 PC) in the range of 200-300 nm. The compounds 
were showing wavelength choices considered monitoring the drugs 
were around 254 nm. The CRS mixture of LDP, DDP were injected in 
to HPLC with PDA detector, recording the peak purity from 229 nm 
to 279 nm. It was observed there was no interference from the 
mobile phase or baseline disturbance at 254 nm with peaks LDP, 
DDP having tR of ~3.05 min. and ~3.66 min. Respectively. It was, 
therefore, concluded that 254 nm, as the most appropriate 
wavelength for the compounds (Fig.4) with suitable sensitivity. 
 





















Fig. 4: LDP UV Spectrum from 210 to 350 nm. Optimum 
wavelength of 254 nm selected 
 
The compounds of interest namely 1-PP, LDP, DDP were relatively 
non polar and of low molecular mass, a polar polysaccharide normal 
phase column Chiralpak AD-H (150 mm x 4.6 mm i. d., 5 µm) was 
tried. Several binary mobile phases of hexane (70-50%v/v) and 
anhydrous ethanol (30-50%v/v) were evaluated with the Chiralpak 
AD-H column. The retention times of the solutes decreased with 
increasing concentration of polar anhydrous ethanol.  
It was noticed that k value for IS 1-PP was low (k< 1) at the highest 
concentration of anhydrous ethanol. In contrast, hexane 
concentrations which were high resulted in k values for DDP that 
were relatively high, resulting in excessively long run times of ~ 12 
min. It was well known that multiple- component mobile phases 
result in better separation efficiency than binary mobile phases, 
because with these solvent strength and selectivity was varied 
simultaneously to obtain the retention times desired [9,10].  
However resolution between LDP and DDP was lacking. Hence a 
third component DEA (as solubilising agent for LDP, DDP 
resolution), was therefore included in the mobile phase and ternary 
mixtures of hexane, anhydrous ethanol in proportions 55:45, 60:40, 
65:35%v/v and DEA solution (0.1±0.05%v/v) were tried. Use of the 
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first of these with 0.1%v/v DEA resulted in a quality separation in 
terms of peak symmetry, optimum resolution, reasonable run time, 
and acceptable k values, particularly for LDP (Table 1). No further 
improvement in peak symmetry was observed with higher DEA 
concentration. (0.1%v/v) was accepted for use. Increasing the flow 
rate from 1.0 to 1.4 ml/min reduced the runtime to less than 5 min. 
The final mobile phase system of 55%v/v hexane, made up to 
100%v/v with anhydrous ethanol, 0.1% v/v DEA and 1.4 ml flow 
rate (60 kgf), was suitable in all respects to detect impurities to 
limits and quantify LDP in a single run of 5 min. Elution order of 
separation was, for non polar impurity B (1-PP)  
~ 2.5 min. away from system peak, followed by LDP peak ~ 3.05 
min. and DPP peak ~3.66 min. A result of 12 runs carried in random 
order replicates, as shown in (Table 1) for the various parameters 
and responses with their Average, Standard deviation calculated. 
Also the Area Ratio of LDP, DDP was found to be R² = 0.965 and R² = 
0.966 respectively.  
The optimized chromatographic conditions were, therefore, use of 
the Chiralpack AD-H column with hexane: anhydrous ethanol: DEA 
solution, 55:45:0.1(v/v) as mobile phase at 1.4 ml/min. This method 
was therefore validated in accordance with ICH guidelines. 
 
Table 1: Results replicates of 12 runs, CRS mixture of LDP, DDP 
Independent Parameters Responses 
Hexane DEA Flow Rate Rs K1,2* Rs1 tF2,3* tF1 α 2 tR Area ratio 2 
55 0.05 1.0 2.64 1.78 3.85 1.35 1.19 1.38 5.59 0.82 
60 0.10 1.2 2.69 1.75 3.89 1.27 1.22 1.40 5.07 0.831 
65 0.15 1.0 3.35 1.70 4.53 1.26 1.33 1.42 6.88 0.82 
65 0.05 1.0 3.42 1.67 4.57 1.31 1.44 1.43 6.86 0.82 
55 0.15 1.4 2.15 1.71 3.40 1.30 1.18 1.37 3.96 0.81 
60 0.10 1.2 2.70 1.71 3.87 1.28 1.22 1.39 5.01 0.81  
65 0.15 1.4 2.15 1.70 3.93 1.21 1.33 1.46 4.84 0.82 
60 0.10 1.2 2.67 1.70 3.87 1.28 1.23 1.39 5.01 0.83 
65 0.05 1.4 2.77 1.71 3.98 1.21 1.31 1.42 4.82 0.82 
55 0.15 1.0 2.71 1.73 3.89 1.29 1.17 1.37 5.53 0.82 
60 0.10 1.2 3.05 1.80 4.02 1.22 1.15 1.41 5.23 0.83 
55 0.05 1.4 2.78 2.40 3.32 1.27 1.12 1.37 3.99 0.82 
Avg 2.76 1.69 3.74 1.28 1.25 1.39  0.819 
STDEV  0.15 0.36 0.039 0.085 0.028  0.006  
 Rs1,2* - Average resolution between Non chiral Impurity B vs LDP, Rs2,3* - 
 
Assay method validation  
The next step of the present study was to check method’s validation 
for specificity, linearity, accuracy, intra/inter-day precision, and 
robustness [11]. The optimized HPLC method was specific in 
relation to the placebo blank used after every run in this study. An 
excellent linearity was established at five levels in the range of 0.5- 5 
µg/ml LDP, DDP, 1-PP with R² of more than 0.965 for all analytes. 
The LOD and LOQ were estimated as 0.95 and 2.05 ng/ml for LDP 
and 1.15 and 2.55 ng/ml for DDP and 0.3 and 0.95 ng/ml for 1-PP 
respectively. Accuracy (n=9), assessed by spike recovery were found 
to be 99.69, 99.66, and 99.65% for LDP, DDP and 1-PP respectively, 
which were within acceptable ranges of 100 ± 2%. The intra and 
inter-assay precision (n=6) was confirmed since the % CV were well 
within the target criterion of <2 respectively.  
Average resolution between LDP vs chiral Impurity A 
Robustness study revealed that small change did not alter retention 
time, retention factor, and resolutions more than 2% and therefore it 
would be concluded that the method conditions are robust. The assay 
method validation of individual parameter and results are shown in 
(Table 2). 
Application of the method 
The proposed isocratic CSP method was applied to the quantitative 
analysis of LDP in real samples (Levotuss) containing DDP and 1-PP in 
detectable limits. Representative chromatograms are presented in Fig.5 
and Fig.6. The results achieved when analyzing Levotuss tablets were 
60.5 (0.3) mg of LDP and 0.5 (0.38) mg of DDP, with values within 
parenthesis being the % CV of the six replicates. Good agreement was 
found between assay results and the label claim of the product. 
  
Table 2: Validation of method for the determination of LDP, DDP and 1-PP 
Validation 
Parameters  
Concentration LDP  DDP 1-PP 
Results Results Results 
Linearity (n=6) 0.5-5.0 µg/ml y=0.723x -0.062 y=0.723x -0.063 y=0.723x -0.098 
  R² = 0.965 R² = 0.966 R² = 0.989 
LOD  0.95 ng/ml 1.05 ng/ml 0.3 ng/ml 
LOQ  2.05 ng/ml 2.55 ng/ml 0.95 ng/ml 
Specificity The method is specific with respect to tablet excipients (starch, lactose, aerosil, hpmc, titanium dioxide and magnesium 
stearate) 
Accuracy (mean % recovery) (n=3)    
  80% w/w  99.53  99.69 99.64 
  100%w/w  99.86  99.41 99.92 
  120%w/w  99.96  99.82 99.35 
 (mean % recovery, %CV) (n=9)  99.69, 0.33 99.66, 0.33 99.65, 0.68 
Precision (%CV) (n=6)    
 (a) Intraday precision  0.5 1.2 1.48 1.57 
 2.5 0.65 1.06 1.351.08 
 5.0 0.83 0.75  
(b) Interday precision 0.5 1.89 1.82 1.681.93 
 2.5 0.82 1.46  
 5.0 0.96 0.65 0.68 
Robustness (%assay, % CV)    
n-hexane conc. (55.0 ± 0.5%) 99.79, 0.33   99.68, 0.65 99.05, 0.59 
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Fig. 5: Chromatograms corresponding to (a) a placebo solution; 
(b) Impurity B spike in LDP 
(c) Assay condition of Levotuss along with Impurity A (DDP) 
and Impurity B (1-PP); 
(d) Optimized CRS mixture of LDP and DDP  
 
 
Fig. 6: Chromatogram obtained at 254 nm following the 
injection of 20 µl of a solution containing 10µg of CRS mixture 
(LDP and DDP) 
 
To establish the practical limit of detection of non chiral impurity B 
in LDP containing pharmaceuticals as well as in bulk drugs, standard 
solutions of LDP were first chromate graphed at high instrumental 
sensitivity to verify the absence of any peaks at retention times 
corresponding to the Imp B, and then deliberately spiked IS namely 
1-PP, with LDP. The level of impurity added to the active principle 
was in 0.1% (w/w), less than BP limit of 0.5%. (Fig.5), shows the 
chromatogram obtained with the solution. From the results of these 
experiments it can be established that when injecting amounts of 
100µg of LDP, a 0.01% level of impurities be quantified, much less 
than the prescribed limit of 0.5% as per BP2007. 
The content of the active principle LDP together with the levels of 
the impurities A and B in pharmaceutical formulations, 
commercially available was determined in triplicate by using the 
proposed method. The quantities found in LDP were in conformity 
with the target values. 
CONCLUSION 
An efficient Isocratic CSP HPLC method was developed, optimized 
and validated for the simultaneous estimation LDP and chiral 
impurity in pharmaceutical formulation and bulk drugs. This 
method reduces overall assay development time and provides 
essential information regarding the sensitivity of various 
chromatographic factors and their interaction effects on the 
attributes of separation. The analytical results obtained lead to the 
conclusion that the developed method performs well with regard to 
both precision and accuracy and also the detection of chiral impurity 
A. Therefore it could be successfully adopted for the routine analysis 
of LDP and their chiral impurity A in bulk drug and pharmaceutical 
formulation. 
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